CN113493496B - Epitope polypeptide of 2019-nCoV novel coronavirus S protein and application thereof - Google Patents
Epitope polypeptide of 2019-nCoV novel coronavirus S protein and application thereof Download PDFInfo
- Publication number
- CN113493496B CN113493496B CN202110297823.5A CN202110297823A CN113493496B CN 113493496 B CN113493496 B CN 113493496B CN 202110297823 A CN202110297823 A CN 202110297823A CN 113493496 B CN113493496 B CN 113493496B
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- healthy
- acid sequence
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 85
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 74
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 71
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 32
- 102100031673 Corneodesmosin Human genes 0.000 title claims abstract description 25
- 101710139375 Corneodesmosin Proteins 0.000 title claims abstract description 24
- 241001678559 COVID-19 virus Species 0.000 title claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 12
- 238000012360 testing method Methods 0.000 claims description 22
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 abstract description 28
- 239000000427 antigen Substances 0.000 abstract description 23
- 108091007433 antigens Proteins 0.000 abstract description 23
- 102000036639 antigens Human genes 0.000 abstract description 23
- 230000005847 immunogenicity Effects 0.000 abstract description 5
- 230000028993 immune response Effects 0.000 abstract description 4
- 238000007086 side reaction Methods 0.000 abstract description 3
- 230000005875 antibody response Effects 0.000 description 71
- 239000012071 phase Substances 0.000 description 41
- 238000011084 recovery Methods 0.000 description 31
- 239000013610 patient sample Substances 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 24
- 238000001514 detection method Methods 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 18
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 17
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 17
- 230000027455 binding Effects 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 14
- 230000004044 response Effects 0.000 description 12
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 10
- 241000700605 Viruses Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000035876 healing Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 244000309467 Human Coronavirus Species 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 229940031626 subunit vaccine Drugs 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 208000034657 Convalescence Diseases 0.000 description 3
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- 101000674278 Homo sapiens Serine-tRNA ligase, cytoplasmic Proteins 0.000 description 3
- 101000674040 Homo sapiens Serine-tRNA ligase, mitochondrial Proteins 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 102100040516 Serine-tRNA ligase, cytoplasmic Human genes 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108010081551 glycylphenylalanine Proteins 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 102000048657 human ACE2 Human genes 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102400000347 Angiotensin 1-7 Human genes 0.000 description 1
- 102400000346 Angiotensin 1-9 Human genes 0.000 description 1
- 101800000550 Angiotensin 1-9 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 101710185050 Angiotensin-converting enzyme Proteins 0.000 description 1
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- BXUHCIXDSWRSBS-CIUDSAMLSA-N Asn-Leu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BXUHCIXDSWRSBS-CIUDSAMLSA-N 0.000 description 1
- REQUGIWGOGSOEZ-ZLUOBGJFSA-N Asn-Ser-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N REQUGIWGOGSOEZ-ZLUOBGJFSA-N 0.000 description 1
- KLYPOCBLKMPBIQ-GHCJXIJMSA-N Asp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N KLYPOCBLKMPBIQ-GHCJXIJMSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- OIMUAKUQOUEPCZ-WHFBIAKZSA-N Cys-Asn-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIMUAKUQOUEPCZ-WHFBIAKZSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PEZZSFLFXXFUQD-XPUUQOCRSA-N Gly-Cys-Val Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O PEZZSFLFXXFUQD-XPUUQOCRSA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101000773743 Homo sapiens Angiotensin-converting enzyme Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 description 1
- WZPIKDWQVRTATP-SYWGBEHUSA-N Ile-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 WZPIKDWQVRTATP-SYWGBEHUSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- IDUCUXTUHHIQIP-SOUVJXGZSA-N Phe-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O IDUCUXTUHHIQIP-SOUVJXGZSA-N 0.000 description 1
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- GURGCNUWVSDYTP-SRVKXCTJSA-N Pro-Leu-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GURGCNUWVSDYTP-SRVKXCTJSA-N 0.000 description 1
- OIDKVWTWGDWMHY-RYUDHWBXSA-N Pro-Tyr Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=C(O)C=C1 OIDKVWTWGDWMHY-RYUDHWBXSA-N 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- PMCMLDNPAZUYGI-DCAQKATOSA-N Ser-Lys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMCMLDNPAZUYGI-DCAQKATOSA-N 0.000 description 1
- ZSDXEKUKQAKZFE-XAVMHZPKSA-N Ser-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N)O ZSDXEKUKQAKZFE-XAVMHZPKSA-N 0.000 description 1
- FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 description 1
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 1
- JMGJDTNUMAZNLX-RWRJDSDZSA-N Thr-Glu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JMGJDTNUMAZNLX-RWRJDSDZSA-N 0.000 description 1
- QHEGAOPHISYNDF-XDTLVQLUSA-N Tyr-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QHEGAOPHISYNDF-XDTLVQLUSA-N 0.000 description 1
- VVZDBPBZHLQPPB-XVKPBYJWSA-N Val-Glu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VVZDBPBZHLQPPB-XVKPBYJWSA-N 0.000 description 1
- BVWPHWLFGRCECJ-JSGCOSHPSA-N Val-Gly-Tyr Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N BVWPHWLFGRCECJ-JSGCOSHPSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- LJXGOQOPNPFXFT-JWRYNVNRSA-N angiotensin (1-9) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 LJXGOQOPNPFXFT-JWRYNVNRSA-N 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 108010021281 angiotensin I (1-7) Proteins 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 229940127002 anti-2019-nCov Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000005099 host tropism Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a group of epitope polypeptides of 2019-nCoV novel coronavirus S protein and application thereof. The amino acid sequence of the antigen epitope polypeptide is selected from one of the following: (1) an amino acid sequence shown as SEQ ID NO. 1; or an amino acid sequence having more than 90% homology with the amino acid sequence shown in SEQ ID NO.1 and having the same function; (2) an amino acid sequence shown as SEQ ID NO. 2; or an amino acid sequence having more than 90% homology to the amino acid sequence shown in SEQ ID NO.2 and having the same function; (3) an amino acid sequence shown as SEQ ID NO. 3; or an amino acid sequence having more than 90% homology with the amino acid sequence shown in SEQ ID NO.3 and having the same function. The high immunogenicity polypeptide screened by the invention can effectively induce organisms to generate immune response, simultaneously avoid the interference of irrelevant antigens and reduce the side reaction of vaccines.
Description
Technical Field
The invention belongs to the technical field of polypeptide vaccines, and particularly relates to an epitope polypeptide of 2019-nCoV novel coronavirus S protein and application thereof.
Background
The current development of a vaccine against the novel coronavirus (2019-nCoV) is essentially the same as the strategy of developing SARS-CoV vaccine in the last 20 years, including (1) an inactivated viral vaccine, (2) a viral vector vaccine, and (3) a subunit vaccine. The polypeptide vaccine designed by the invention belongs to a novel subunit vaccine. Subunit vaccine refers to vaccine prepared by extracting specific protein structure of bacteria and virus by chemical decomposition or controlled proteolysis method, and screening out fragment with immunological activity. In the immune reaction process of pathogens and organisms, only a small amount of antigens have immunogenicity so as to stimulate the organisms to generate immune response, so subunit vaccines prepared by screening the antigens with the immune activity can effectively play a role of the vaccine, meanwhile, the antibodies induced by irrelevant antigens are avoided, and the side reaction of the vaccine is reduced. At present, china is still in a relatively laggard position in the aspect of subunit vaccine development.
The novel coronavirus 2019-nCoV particle comprises 4 structural proteins, respectively spike protein, membrane protein, envelope protein and nucleocapsid protein. Wherein the spike protein is encoded by the S gene and is a coat protein for packaging viruses, also known as the S protein. The S protein is directed onto the endoplasmic reticulum by means of its amino-terminal signal peptide and is highly N-glycosylated, and its trimers form a unique spike structure on the viral surface. The S protein is cleavable by furin (furin) of the host into polypeptide fragments S1 and S2, wherein S1 is the receptor binding domain and S2 serves as the stem of the spike molecule. The S protein mediates viral invasion primarily through binding to host cell receptors and determines viral organization or host tropism. The research shows that the S protein is a key component of a new coronavirus infected organism and is also a key target point for developing new coronavirus vaccine and antibody inhibitor.
Disclosure of Invention
The invention aims to provide a group of epitope polypeptides of 2019-nCoV novel coronavirus S protein and application thereof.
According to the invention, immune affinity analysis is carried out on patient MHC molecules and virus protein molecules, and antigen epitopes with high immunogenicity are predicted to be used as polypeptide vaccines for stimulating T cell immune response. Meanwhile, the antigen epitope with high affinity of B cell epitope is screened and used as a polypeptide vaccine for inducing B cell humoral immune response. The peptide segment bound by MHC molecule is 8-11 in length, and the molecule has a groove which is an antigen binding site, called peptide binding groove (peptide-binding groove or cleft), and the groove bottom has 6 pockets: pocket A-F, pocket A and Pocket F are responsible for fixing peptide fragments, pocket B-E are responsible for combining different peptide fragments, and the specificity is maintained. The characteristic of binding of the antigen binding groove of the MHC molecule to the antigen peptide often has two or more key amino acid (anchor residue) specificities combined with the polypeptide binding motif in the peptide binding groove of the MHC molecule. The invention uses a machine learning model, and uses the known combination condition of MHC molecules and antigens to train to obtain an affinity model, so as to predict the affinity of antigen peptides of the novel coronavirus and the MHC molecules. The B cell epitopes are predicted from protein sequences using a random forest algorithm that trains the epitope and non-epitope amino acids determined from the crystal structure, screening peptides scored above a set threshold as potential BCR recognition vaccine molecules.
According to the invention, through a biological information algorithm, the recognition mode of a virus antigen and a host immune system is simulated, a polypeptide sequence with high immunogenicity is screened and predicted from 2019-nCoV novel coronavirus S protein to serve as a candidate antigen, and then the antigen epitope polypeptide with a vaccine effect is further obtained through the verification of a validity experiment of a polypeptide vaccine.
The first aspect of the present invention provides a group of epitope polypeptides of 2019-nCoV novel coronavirus S protein, wherein the amino acid sequence of the epitope polypeptides is selected from one of the following:
(1) An amino acid sequence as shown in SEQ ID NO. 1; or an amino acid sequence having more than 90% homology with the amino acid sequence shown in SEQ ID NO.1 and having the same function;
(2) An amino acid sequence as shown in SEQ ID NO. 2; or an amino acid sequence having more than 90% homology to the amino acid sequence shown in SEQ ID NO.2 and having the same function;
(3) An amino acid sequence as shown in SEQ ID NO. 3; or an amino acid sequence having more than 90% homology with the amino acid sequence shown in SEQ ID NO.3 and having the same function.
In a second aspect, the invention provides a polynucleotide sequence encoding an epitope polypeptide of the 2019-nCoV novel coronavirus S protein.
The third aspect of the invention provides the use of one or more of said epitope polypeptides in the preparation of a human coronavirus vaccine. Preferably, the human coronavirus is a 2019-nCoV novel coronavirus.
The fourth aspect of the invention provides the use of one or more of said epitope polypeptides in the preparation of a medicament for the treatment of human coronavirus infection. Preferably, the human coronavirus is a 2019-nCoV novel coronavirus. The antigen epitope polypeptide is used as a mechanism of a novel anti-2019-nCoV coronavirus drug: as a blocking peptide blocking viral infection, the S protein of the virus can be prevented from binding to ACE2 receptor, thus resisting infection by 2019-nCoV new coronavirus.
In a fifth aspect, the invention provides an antibody which specifically binds to said epitope polypeptide.
In a sixth aspect, the invention provides a test kit comprising any one of said epitope polypeptides, or said antibodies, or a combination of epitope polypeptides and antibodies.
The detection kit provided by the invention is used for detecting whether the human coronavirus or the anti-human coronavirus antibody exists in the sample in vitro. Preferably, the human coronavirus is a 2019-nCoV novel coronavirus.
Compared with the prior art, the invention has the following beneficial effects:
1, the invention screens and designs the polypeptide vaccine based on the known virus sequence characteristics and computer algorithm, the sequence of the polypeptide molecule is clear, and the production and the preparation are convenient. The technical problem of separating specific virus components by using a complex experimental means is overcome.
2, the vaccine design of the present invention considers the affinity of the Major Histocompatibility Complex (MHC) to polypeptide molecules and is therefore able to be efficiently recognized by T cells, thereby inducing a cellular immune response in the body. Compared with the conventional subunit vaccine or inactivated virus vaccine, the polypeptide vaccine can only activate humoral immune response and has stronger immune efficacy.
3, the high immunogenicity polypeptide obtained by manual screening can effectively induce organisms to generate immune response, meanwhile, the interference of irrelevant antigens is avoided, and the side reaction of vaccines is reduced. On the other hand, the polypeptide vaccine has clear components, has no harm to human body and ensures the safety.
4, the polypeptide vaccine provided by the invention can effectively generate stronger neutralization reaction with IgG and IgM antibodies in serum of patients in the convalescence of new coronaries. In serum of convalescence patients, the specific antibody of healthier people has the function of resisting the new coronavirus, so the polypeptide vaccine of the invention has the capability of inducing neutralizing antibodies resisting the new coronavirus in human bodies, thereby improving the immunity of organisms to the new coronavirus. In addition, the polypeptide vaccine of the invention can competitively bind to ACE2, which indicates that the polypeptide vaccine of the invention can prevent viruses from binding to host cells and has a defensive effect on new coronavirus infection.
Drawings
FIG. 1 is a flow chart of the design of the screening of epitope polypeptides of the present invention.
FIG. 2A is a graph comparing the maximum intensity of response in an IgG antibody response test with that of a healthy group for each patient sample in the IgG antibody detection of SEQ ID NO. 1.
FIG. 2B is a graph showing the comparison of IgG antibody responses at different recovery phases after the same patient is cured in the detection of IgG antibody of SEQ ID NO. 1.
FIG. 2C is a graph showing the comparison of IgG antibody responses of each patient sample to the healthy group, grouped according to the different phases of recovery in the IgG antibody assay of SEQ ID NO. 1.
FIG. 3A is a graph comparing the maximum intensity of response in IgM antibody response tests with that of healthy groups for each patient sample in IgM antibody detection of SEQ ID NO. 1.
FIG. 3B is a graph showing the comparison of IgM antibody responses at different recovery phases after the same patient is cured in the IgM antibody detection of SEQ ID NO. 1.
FIG. 3C is a graph showing the IgM antibody response of each patient sample compared to the healthy group, grouped at different stages of recovery in the IgM antibody assay of SEQ ID NO. 1.
FIG. 4A is a graph comparing the maximum intensity of response in an IgG antibody response test with that of a healthy group for each patient sample in the IgG antibody detection of SEQ ID NO. 2.
FIG. 4B is a graph showing the comparison of IgG antibody responses at different recovery phases after the same patient is cured in the detection of IgG antibody of SEQ ID NO. 2.
FIG. 4C is a graph showing the comparison of IgG antibody responses of each patient sample to the healthy group, grouped according to the different phases of recovery in the IgG antibody assay of SEQ ID NO. 2.
FIG. 5A is a graph comparing the maximum intensity of response in IgM antibody response tests with that of healthy groups for each patient sample in IgM antibody detection of SEQ ID NO. 2.
FIG. 5B is a graph showing the comparison of IgM antibody responses at different recovery phases after healing of the same patient in IgM antibody detection of SEQ ID NO. 2.
FIG. 5C is a graph showing the IgM antibody response of each patient sample compared to the healthy group, grouped at different stages of recovery in the IgM antibody assay of SEQ ID NO. 2.
FIG. 6A is a graph comparing the maximum intensity of response in an IgG antibody response test with that of a healthy group for each patient sample in the IgG antibody detection of SEQ ID NO. 3.
FIG. 6B is a graph showing the comparison of IgG antibody responses at different recovery phases after the same patient is cured in the detection of IgG antibody of SEQ ID NO. 3.
FIG. 6C is a graph showing the comparison of IgG antibody responses of each patient sample to the healthy group, grouped according to the different phases of recovery in the IgG antibody assay of SEQ ID NO. 3.
FIG. 7A is a graph comparing the maximum intensity of response in IgM antibody response tests with that of healthy groups for each patient sample in IgM antibody detection of SEQ ID NO. 3.
FIG. 7B is a graph showing the comparison of IgM antibody responses at different recovery phases after the same patient is cured in IgM antibody detection of SEQ ID NO. 3.
FIG. 7C is a graph showing the IgM antibody response of each patient sample compared to the healthy group, grouped at different stages of recovery in the IgM antibody assay of SEQ ID NO. 3.
FIG. 8 is an electrophoretogram of the antigen epitope polypeptide prepared by the present invention competitively inhibiting the binding of the RBD region of S protein to human ACE2 protein.
Detailed Description
The following describes the technical scheme of the present invention in detail by referring to examples. The reagents and biological materials used hereinafter are commercial products unless otherwise specified.
Example 1 design selection of epitope Polypeptides
Referring to FIG. 1, a flow chart for screening epitope polypeptides is designed for the present invention. The affinity model is obtained by training a machine learning model by using the known combination condition of the MHC molecules and the antigens, so that the affinity of the antigen peptide of the novel coronavirus and the MHC molecules is predicted. The B cell epitopes are predicted from protein sequences using a random forest algorithm that trains the epitope and non-epitope amino acids determined from the crystal structure, screening peptides scored above a set threshold as potential BCR recognition vaccine molecules. And (3) for the polypeptide sequences screened by the computer model, obtaining polypeptide fragments by utilizing a solid-phase synthesis method, and then evaluating the effectiveness of the polypeptides as vaccines by a neutralizing antibody test and a cytokine stimulation test to obtain the final epitope polypeptides.
3 antigen epitope polypeptide sequences are designed and screened by utilizing the algorithm aiming at the sequence characteristics and the spatial conformation of the 2019-nCoV novel coronavirus S protein, and the sequence information is as follows:
SEQ ID NO.1:GCVIAWNSNNLDSKVGG
SEQ ID NO.2:LKPFERDISTEIYQAGSTPCNGVEGFN
SEQ ID NO.3:PLQSYGFQPTNGVGYQPY
EXAMPLE 2 Synthesis of epitope Polypeptides
3 antigen epitope polypeptide sequences (SEQ ID NO.1-SEQ ID NO. 3) designed and screened are synthesized by adopting a solid phase synthesis method. The specific process of solid phase synthesis of polypeptide is as follows:
chloromethyl polystyrene resin is used as insoluble solid phase carrier, and one amino acid with amino group protected by blocking group is first connected to the solid phase carrier. Under the action of trifluoroacetic acid, the protecting group of the amino group is removed, so that the first amino acid is attached to the solid support. The carboxyl group of the second amino acid with blocked amino group is then activated by N, N' -Dicyclohexylcarbodiimide (DCC), and the second amino acid with activated carboxyl group is reacted with the amino group of the first amino acid attached to the solid support to form a peptide bond, thus forming a dipeptide with a protecting group on the solid support. The above peptide bond formation reaction is repeated to grow the peptide chain from the C-terminus to the N-terminus until the desired peptide chain length is reached. Finally removing the protecting group, and hydrolyzing the ester bond between the peptide chain and the solid phase carrier by using HF to obtain the synthesized peptide.
Example 3 evaluation of the effectiveness of epitope polypeptide vaccine
The experimental method comprises the following steps: the synthesized epitope polypeptides are marked by adopting C-terminal biotin groups, and are printed on cut pieces by using a biotin-streptavidin chemical method to prepare a polypeptide chip. The prepared polypeptide chip is used for detecting the neutralization reaction degree of IgG and IgM antibodies and epitope polypeptides in serum.
Serum samples from 19 patients with new coronaries at recovery from pneumonia and serum samples from 10 healthy persons were collected from hospitals. Patients in convalescence are diagnosed with new coronavirus before receiving treatment, so they have been exposed to new coronavirus, and antibodies against new coronavirus remain in serum after cure. By detecting the intensity of the antibody response against each epitope polypeptide in these samples and comparing with healthy humans, the ability of the epitope polypeptides prepared in the present invention to induce neutralizing antibodies in humans can be assessed.
1. IgG antibody detection result of SEQ ID NO.1
In the test of the epitope polypeptide shown in SEQ ID NO.1 and IgG antibody reaction, the strongest antibody reaction of all samples (100%) of 19 patient samples is higher than that of the healthy group. Referring to fig. 2A, a graph comparing the maximum intensity of response of each patient sample in an IgG antibody response test with that of a healthy group is shown, wherein gray is the healthy group, red is the positive group of patients having an intensity of antibody response greater than that of the healthy group, and blue is the negative group of patients having an intensity of antibody response lower than that of the healthy group. As can be seen from fig. 2A: the intensity of antibody response was greater in 19 patients than in the healthy group. Referring to fig. 2B, a comparison of IgG antibody responses at different recovery phases after healing of the same patient is shown, with several phases being red for higher than healthy groups and blue for lower than healthy groups. As can be seen from fig. 2B: 13 (68.4%) patients had higher antibody responses than the healthy group at all phases of the recovery period (1-7 months), while the remaining 6 patients had a lower phase than the healthy group. Referring to fig. 2C, a graph comparing IgG antibody responses of each patient sample to the healthy group was obtained for the grouping according to the different phases of recovery. As can be seen from fig. 2C: the antibody response was higher in 16 (88.9%) serum samples in the first month than in the healthy group, in 14 (77.8%) serum samples in the 4 th month than in the healthy group, and in 13 (78.6%) serum samples in the 7 th month than in the healthy group.
2. IgM antibody detection results of SEQ ID NO.1
In the test of the reaction of the epitope polypeptide shown in SEQ ID No.1 with IgM antibodies, 17 (89.5%) patients in 19 patient samples had the strongest antibody reaction than in the healthy group. Referring to fig. 3A, a graph comparing the maximum intensity of response of each patient sample in IgM antibody response test with that of the healthy group is shown, wherein gray is the healthy group, red is the positive group of patients with higher intensity of antibody response than the healthy group, and blue is the negative group of patients with lower intensity of antibody response than the healthy group. As can be seen from fig. 3A: the antibody response intensity was greater for 17 patients than for the healthy group, and for 2 patients than for the healthy group. Referring to fig. 3B, a comparison of IgM antibody responses at different recovery phases after healing of the same patient is shown, with several phases being red for higher than healthy groups and blue for lower than healthy groups. As can be seen from fig. 3B: there were 10 (52.6%) patients with higher antibody responses than the healthy group at all phases of the recovery period (1-7 months), and the remaining 9 patients showed a lower phase than the healthy group. Referring to fig. 3C, a graph comparing IgM antibody responses of each patient sample to healthy groups, grouped according to different phases of recovery. As can be seen from fig. 3C: the antibody response was higher for 13 (72.2%) serum samples in the first month than for the healthy group, for 12 (66.6%) serum samples in the 4 th month than for the healthy group, and for 12 (80%) serum samples in the 7 th month than for the healthy group.
3. IgG antibody detection result of SEQ ID NO.2
In the test of the epitope polypeptide shown in SEQ ID NO.2 and IgG antibody reaction, 7 (36.8%) patients in 19 patient samples have the strongest antibody reaction higher than that of the healthy group. Referring to fig. 4A, a graph comparing the maximum intensity of response of each patient sample in an IgG antibody response test with that of the healthy group is shown, wherein gray is the healthy group, red is the positive group of patients having an intensity of antibody response greater than that of the healthy group, and blue is the negative group of patients having an intensity of antibody response lower than that of the healthy group. As can be seen from fig. 4A: the antibody response intensity was greater for 7 patients than for the healthy group, and for 12 patients than for the healthy group. Referring to fig. 4B, a comparison of IgG antibody responses at different recovery phases after healing of the same patient is shown, with several phases being red for higher than healthy groups and blue for lower than healthy groups. As can be seen from fig. 4B: there were 0 (0%) patients with higher antibody responses than the healthy group at all phases of the recovery period (1-7 months), and the remaining 19 patients showed a phase lower than the healthy group. Referring to fig. 4C, a graph comparing IgG antibody responses of each patient sample to the healthy group was obtained for the grouping according to the different phases of recovery. As can be seen from fig. 4C: the antibody response was higher for 5 (27.8%) serum samples in the first month than for the healthy group, 2 (11.1%) serum samples in the 4 th month than for the healthy group, and 3 (20%) serum samples in the 7 th month than for the healthy group.
4. IgM antibody detection results of SEQ ID NO.2
In the test of the reaction of the epitope polypeptide shown in SEQ ID No.2 with IgM antibodies, the strongest antibody reaction of 15 (78.9%) patients in 19 patient samples was higher than that of the healthy group. Referring to fig. 5A, a graph comparing the maximum intensity of response of each patient sample in IgM antibody response test with that of the healthy group is shown, wherein gray is the healthy group, red is the positive group of patients with higher intensity of antibody response than the healthy group, and blue is the negative group of patients with lower intensity of antibody response than the healthy group. As can be seen from fig. 5A: the antibody response intensity was greater in 15 patients than in the healthy group, and the antibody response intensity was lower in 4 patients than in the healthy group. Referring to fig. 5B, a comparison of IgM antibody responses at different recovery phases after healing of the same patient is shown, with several phases being red for higher than healthy groups and blue for lower than healthy groups. As can be seen from fig. 5B: there were 7 (36.8%) patients with higher antibody responses than the healthy group at all phases of the recovery period (1-7 months), and the remaining 12 patients showed a lower phase than the healthy group. Referring to fig. 5C, a graph comparing IgM antibody responses of each patient sample to healthy groups, grouped according to different phases of recovery. As can be seen from fig. 5C: the different phases were compared in healthy groups, and 11 (61.1%) serum samples were higher in antibody response than in healthy groups in the first month, 8 (44.4%) serum samples were higher in antibody response than in healthy groups in the 4 th month, and 9 (60%) serum samples were higher in antibody response than in healthy groups in the 7 th month.
5. IgG antibody detection result of SEQ ID NO.3
In the test of the reaction of the epitope polypeptide shown in SEQ ID NO.3 with IgG antibodies, the strongest antibody reaction of 15 (78.9%) patients in 19 patient samples was higher than that of the healthy group. Referring to fig. 6A, a graph comparing the maximum intensity of response of each patient sample in an IgG antibody response test with that of the healthy group is shown, wherein gray is the healthy group, red is the positive group of patients having an intensity of antibody response greater than that of the healthy group, and blue is the negative group of patients having an intensity of antibody response lower than that of the healthy group. As can be seen from fig. 6A: the antibody response intensity was greater in 15 patients than in the healthy group, and the antibody response intensity was lower in 4 patients than in the healthy group. Referring to fig. 6B, a comparison of IgG antibody responses at different recovery phases after healing of the same patient, with several phases higher than healthy groups marked red and with some phases lower than healthy groups marked blue. As can be seen from fig. 6B: there were 7 (36.8%) patients with higher antibody responses than the healthy group at all phases of the recovery period (1-7 months), and the remaining 12 patients showed a lower phase than the healthy group. Referring to fig. 6C, a graph comparing IgG antibody responses of each patient sample to healthy groups was obtained for the different stages of recovery. As can be seen from fig. 6C: the antibody response was higher for 12 (66.7%) serum samples in the first month than for the healthy group, 11 (61.1%) serum samples in the 4 th month than for the healthy group, and 7 (46.7%) serum samples in the 7 th month than for the healthy group.
6. IgM antibody detection results of SEQ ID NO.3
In the test of the reaction of the epitope polypeptide shown in SEQ ID No.3 with IgM antibodies, 17 (89.5%) patients in 19 patient samples had the strongest antibody reaction than in the healthy group. Referring to fig. 7A, a graph comparing the maximum intensity of response of each patient sample in IgM antibody response test with that of the healthy group is shown, wherein gray is the healthy group, red is the positive group of patients with higher intensity of antibody response than the healthy group, and blue is the negative group of patients with lower intensity of antibody response than the healthy group. As can be seen from fig. 7A: the antibody response intensity was greater for 17 patients than for the healthy group, and for 2 patients than for the healthy group. Referring to fig. 7B, a comparison of IgM antibody responses at different recovery phases after healing of the same patient is shown, with several phases being red for higher than healthy groups and blue for lower than healthy groups. As can be seen from fig. 7B: 11 (57.9%) patients had higher antibody responses than the healthy group at all phases of the recovery period (1-7 months), while the remaining 8 patients had a lower phase than the healthy group. Referring to fig. 7C, a graph comparing IgM antibody responses of each patient sample to healthy groups, grouped according to different phases of recovery. As can be seen from fig. 7C: the different phases were compared to the healthy group, and the antibody response was higher in 14 (77.8%) serum samples in the first month than in the healthy group, in 12 (66.7%) serum samples in the 4 th month than in the healthy group, and in 12 (80%) serum samples in the 7 th month than in the healthy group.
7. Binding experiments of RBD region of competitive inhibition S protein and human ACE2 protein
ACE2 is also known as ACEH and is known as angiotensin converting enzyme 2. The protein coded by the gene belongs to the family of angiotensin converting enzymes of dipeptidyl carboxyl dipeptidase and has quite large homology with human angiotensin converting enzyme 1. This secreted protein catalyzes the cleavage of angiotensin I into angiotensin 1-9 and angiotensin II into the vasodilator angiotensin 1-7.ACE2 has a strong affinity for Ang II type 1 and type 2 receptors, regulating blood pressure, humoral balance, inflammation, cell proliferation, hypertrophy and fibrosis. At the same time, the organ and cell specific expression of the gene suggests that it may play a role in regulating cardiovascular and renal functions and fertility. ACE2 is considered as an important functional receptor for coronaviruses such as SARS. In the structure of SARS spike glycoprotein (S) protein-bound ACE2, the catalytically active site of ACE2 is not blocked by the SARS S protein. ACE2 therefore functions as a SARS receptor irrespective of its peptidase activity. 2019-nCoV, like SARS-CoV, infects human airway epithelial cells by invasion through mediation of the S-protein with the human cell surface ACE2 receptor, but 1 of the 3 Receptor Binding Domains (RBDs) in the S protein protrudes spirally upward to allow the S protein to bind more readily to the host receptor ACE 2.
Therefore, the detection of the competitive binding effect of the epitope polypeptide and ACE2 can prove that the epitope polypeptide prepared by the invention has the capability of preventing the combination of the novel coronavirus and host cells and has the defending effect on the infection of the novel coronavirus.
The test procedure is as follows:
(1) 1ug RBD-HIS+HIS-resin is connected for 2-4 hours at 4 ℃;
(2) Eluting with Lysis buffer for 3 times;
(3) Preincubating with a polypeptide;
(4) Adding cell lysate overnight;
(5) Eluting the lysate for 3 times;
(6) 2 Xbuffer was added and left at 100℃for 5 minutes.
The reaction system after adding the buffer solution was subjected to electrophoresis, and the result of electrophoresis is shown in FIG. 8. ACE2 is the receptor for invasion of S protein into cells, the RBD region of S protein and ACE2 protein bind (interaction), the two proteins form a large complex, run slowly on the electropherogram, after polypeptide is added, bind to ACE2 protein competitively with RBD, so that the binding of ACE2 and RBD is blocked, a large complex cannot be formed, and the band on the electropherogram becomes weak. Therefore, the weaker the band on the electrophoresis diagram, the more obvious the inhibition effect of the epitope polypeptide on the binding of ACE2 and RBD is shown. As can be seen from fig. 8: the antigen epitope polypeptides shown in SEQ ID NO.2 and SEQ ID NO.3 have obvious inhibition effect on the combination of ACE2 and RBD. SEQ ID NO.1 has a certain inhibition effect when used at 250 nM.
The foregoing is only a part of the preferred embodiments of the present invention, and the present invention is not limited to the contents of the embodiments. It will be apparent to those skilled in the art that various changes and modifications can be made within the scope of the technical solution of the present invention, and any changes and modifications are within the scope of the present invention.
Sequence listing
<110> Anda biopharmaceutical development (Shenzhen Co., ltd.)
<120> 2019-nCoV novel coronavirus S protein epitope polypeptide and application thereof
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 17
<212> PRT
<213> Artificial sequence (Artificial Sequence)
<400> 1
Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly
1 5 10 15
Gly
<210> 2
<211> 27
<212> PRT
<213> Artificial sequence (Artificial Sequence)
<400> 2
Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly
1 5 10 15
Ser Thr Pro Cys Asn Gly Val Glu Gly Phe Asn
20 25
<210> 3
<211> 18
<212> PRT
<213> Artificial sequence (Artificial Sequence)
<400> 3
Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln
1 5 10 15
Pro Tyr
Claims (3)
1. A polypeptide of 2019-nCoV new coronavirus S protein, characterized in that: the amino acid sequence of the polypeptide is selected from the amino acid sequences shown in SEQ ID NO. 3.
2. A polynucleotide, characterized in that: encoding the polypeptide of claim 1.
3. A test kit, characterized in that: comprising the polypeptide of claim 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020102011152 | 2020-03-20 | ||
CN202010201115 | 2020-03-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113493496A CN113493496A (en) | 2021-10-12 |
CN113493496B true CN113493496B (en) | 2024-03-22 |
Family
ID=77997241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110297823.5A Active CN113493496B (en) | 2020-03-20 | 2021-03-19 | Epitope polypeptide of 2019-nCoV novel coronavirus S protein and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113493496B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101085812A (en) * | 2006-06-08 | 2007-12-12 | 中国科学院上海生命科学研究院 | SARS coronavirus polypeptide antigen and application thereof |
-
2021
- 2021-03-19 CN CN202110297823.5A patent/CN113493496B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101085812A (en) * | 2006-06-08 | 2007-12-12 | 中国科学院上海生命科学研究院 | SARS coronavirus polypeptide antigen and application thereof |
Non-Patent Citations (1)
Title |
---|
In Silico Identification of Novel B Cell and T Cell Epitopes of Wuhan Coronavirus (2019-nCoV) for Effective Multi Epitope-Based Peptide Vaccine Production;Rasheed et al.;Preprints.org 2020;摘要,第4页第4段-第5页第1段,第6页第3段-第7页第1段,第9页第2段,第9页第4段,表1 * |
Also Published As
Publication number | Publication date |
---|---|
CN113493496A (en) | 2021-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2298793A3 (en) | Polypeptide fragments of hepatitis E virus, vaccine composition comprising said fragments and diagnostic kits | |
US20070161545A1 (en) | Triple polypeptide complexes | |
WO2005028497A2 (en) | Receptor binding peptides derived from the sars s protein | |
Zhao et al. | Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates | |
AU2003263853A1 (en) | Compositions and methods related to flavivirus envelope protein domain iii antigens | |
CN101492495B (en) | A group of antigen epitope polypeptide and uses thereof | |
CN106380517A (en) | Micromolecular antibody having neutralization activity for middle-east respiratory syndrome (MERS) coronavirus and application of micromolecular antibody | |
JPH05506247A (en) | Antagonist of human gamma interferon | |
CN110420334A (en) | A kind of method of drug conjugate and raising drug molecule half-life period | |
CN113493496B (en) | Epitope polypeptide of 2019-nCoV novel coronavirus S protein and application thereof | |
CN113493498B (en) | Epitope polypeptide of 2019-nCoV novel coronavirus 3CLpro protein and application thereof | |
CN113493497B (en) | Epitope polypeptide of 2019-nCoV novel coronavirus ORF10 protein and application thereof | |
US20110028409A1 (en) | Detection of anti-ribosomal p protein antibodies by means of synthetic peptides | |
AU2002339227A1 (en) | Triple polypeptide complexes | |
Wu et al. | DNA vaccine against Taenia solium cysticercosis expressed as a modified hepatitis B virus core particle containing three epitopes shared by Taenia crassiceps and Taenia solium | |
Bellone et al. | Preferential pairing of T and B cells for production of antibodies without covalent association of T and B epitopes | |
AU662534B2 (en) | Peptides for use in induction of T cell activation against HIV-1 | |
CN102666569A (en) | Viral citrullinated peptides and uses thereof | |
CN100497377C (en) | SARS coronavirus structure protein ORF3 and its use | |
WO2008020293A2 (en) | West nile virus envelope (e) protein antigen and immunoassay | |
CN114751964B (en) | Universal vaccine protein fragment of beta coronavirus, screening method and application thereof | |
EP4434542A1 (en) | Sars-cov-2 immunogenic polypeptides and uses thereof | |
WO2004056316A3 (en) | Vaccines against hiv-1 tat protein to generate neutralizing antibodies | |
KR0158434B1 (en) | Composite peptide for c-type cancer | |
EP4237426A1 (en) | Peptides and conjugates thereof as ace-2 and s1 subunit mimics against severe acute respiratory syndrome coronavirus-2 (sars-cov2) infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |